ʻO ka manaʻo o ka tumora
ʻO ka Tumor kahi mea ola hou i hoʻokumu ʻia e ka hoʻonui ʻia ʻana o nā cell i loko o ke kino, a ʻike pinepine ʻia ma ke ʻano he ʻano ʻiʻo nui (puʻupuʻu) ma ka ʻāpana kūloko o ke kino. ʻO ka hoʻokumu ʻana o ka tumor ka hopena o ka maʻi koʻikoʻi o ka hoʻoponopono ʻana i ka ulu ʻana o ka cell ma lalo o ka hana o nā ʻano tumorigenic like ʻole. ʻO ka hoʻonui ʻole ʻia o nā cell e alakaʻi ana i ka hoʻokumu ʻana o ka tumor i kapa ʻia ʻo neoplastic proliferation.
I ka makahiki 2019, ua paʻi ʻo Cancer Cell i kahi ʻatikala i hala. Ua ʻike ka poʻe noiʻi hiki i ka metformin ke kāohi nui i ka ulu ʻana o ka maʻi maʻi i ka mokuʻāina hoʻokē ʻai, a ua manaʻo ʻia ʻo PP2A-GSK3β-MCL-1 alahele he pahuhopu hou no ka mālama ʻana i ka maʻi maʻi.
ʻO ka ʻokoʻa nui ma waena o ka maʻi maʻi benign a me ka maʻi maʻi maʻi
ʻO ka maʻi maʻi maʻi: ka ulu lohi, ka capsule, ka ulu ʻana o ka pehu, ka paheʻe ʻana i ka pā, ka palena maopopo, ʻaʻohe metastasis, maʻamau ka maikaʻi o ka prognosis, nā hōʻailona koʻikoʻi kūloko, ʻaʻohe kino holoʻokoʻa, ʻaʻole maʻamau e make nā maʻi.
ʻO ka maʻi maʻi maʻi (cancer): ka ulu wikiwiki, ka ulu ʻana o ka invasive, adhesion i nā ʻiʻo a puni, hiki ʻole ke neʻe i ka wā e hoʻopā ʻia ai, ka palena ʻole, maʻalahi ka metastasis, maʻalahi ka hoʻi hou ʻana ma hope o ka mālama ʻana, ke kuni haʻahaʻa, ka ʻai ʻole i ka wā mua, ka pohō kaumaha, ka emaciation koʻikoʻi, ka anemia a me ke kuni i ka wā hope, etc.
"No ka mea, ʻaʻole i loaʻa i nā maʻi maʻi benign a me nā maʻi maʻi ʻino wale nō nā hōʻike lapaʻau like ʻole, akā ʻoi aku ka mea nui, ʻokoʻa kā lākou prognosis, no laila ke ʻike ʻoe i kahi puʻupuʻu i loko o kou kino a me nā hōʻailona ma luna, pono ʻoe e ʻimi i ka ʻōlelo aʻo i ka manawa."
ʻO ka mālama ʻana i ka maʻi maʻi maʻi
Ka Papahana Genome Kanaka a me ka Papahana Genome maʻi maʻi maʻi honua
ʻO ka Human Genome Project, i hoʻokuʻu ʻia ma ʻAmelika Hui Pū ʻIa i ka makahiki 1990, ke manaʻo nei e wehe i nā code āpau o kahi 100,000 genes i loko o ke kino kanaka a huki i ka spectrum o nā genes kanaka.
Ma 2006, ʻo ka International Cancer Genome Project, i hoʻolauna pū ʻia e nā ʻāina he nui, ʻo ia kekahi noiʻi ʻepekema nui ma hope o ka Human Genome Project.
ʻO nā pilikia koʻikoʻi i ka mālama ʻana i ka maʻi tumora
ʻO ka maʻi hoʻokahi a me ka mālama ʻana = Ka maʻi hoʻokahi + nā lāʻau lapaʻau i kuhikuhi ʻia
No ka hapanui o nā maʻi like ʻole e loaʻa ana i ka maʻi like, ʻo ke ʻano o ka mālama ʻana ʻo ka hoʻohana ʻana i ka lāʻau lapaʻau like a me ka dosage maʻamau, akā ʻo ka ʻoiaʻiʻo, he ʻokoʻa nui nā maʻi like ʻole i ka hopena lapaʻau a me nā hopena ʻino, a i kekahi manawa ua make kēia ʻokoʻa.
Loaʻa nā hiʻohiʻona o ka hoʻomaʻamaʻa ʻana i ka lāʻau lapaʻau i koho nui ʻia i ka pepehi ʻana i nā cell tumor me ka ʻole o ka pepehi ʻana a i ʻole ka hōʻino wale ʻana i nā cell maʻamau, me nā hopena liʻiliʻi liʻiliʻi, e hoʻomaikaʻi maikaʻi i ka maikaʻi o ke ola a me ka hopena therapeutic o nā maʻi.
No ka mea ua hoʻolālā ʻia ka lāʻau lapaʻau i hoʻopaʻa ʻia e hoʻouka i nā molekele i hoʻopaʻa ʻia, pono ia e ʻike i nā ʻano maʻi tumora a ʻike inā loaʻa i nā mea maʻi nā pahuhopu kūpono ma mua o ka lawe ʻana i nā lāʻau lapaʻau, i mea e hoʻokō ai i kāna hopena curative.
Ka ʻike ʻana i nā gene tumor
ʻO ka ʻike ʻana i ke ʻano maʻi he ala e nānā ai a hoʻonohonoho i ka DNA/RNA o nā pūnaewele tumo.
ʻO ke koʻikoʻi o ka ʻike ʻana i ke ʻano maʻi tumora ʻo ia ke alakaʻi ʻana i ke koho ʻana i ka lāʻau lapaʻau o ka lāʻau lapaʻau (nā lāʻau lapaʻau i hoʻopaʻa ʻia, nā mea hoʻopaʻapaʻa pale pale a me nā maʻi AIDS hou, ka mālama hope ʻana), a me ka wānana i ka wānana a me ka hoʻi hou ʻana.
Hāʻawi ʻia nā haʻina e Acer Macro & Micro-Test
Kāne EGFR Gene 29 Mutations Detection Kit (Fluorescence PCR)
Hoʻohana ʻia no ka ʻike qualitative o nā hoʻololi maʻamau i ka exon 18-21 o ka gene EGFR i nā maʻi maʻi maʻi maʻi ʻaʻai liʻiliʻi liʻiliʻi i loko o ka vitro.
1. ʻO ka hoʻokomoʻana i ka mana o ka mana o loko o ka'ōnaehana hiki ke nānā pono i ke kaʻina hana hoʻokolohua a hōʻoia i ka maikaʻi hoʻokolohua.
2. High sensitivity: hiki ke ʻike paʻa ka mutation rate o 1% i ke kua o 3ng/μL wild-type nucleic acid reaction solution.
3. Kiʻekiʻe kikoʻī: ʻaʻohe hopena keʻa me nā hopena ʻike o ka DNA genomic kanaka ʻano hihiu a me nā ʻano mutant ʻē aʻe.
KRAS 8 Mutations Detection Kit (Fluorescence PCR)
ʻEwalu ʻano o ka hoʻololi ʻana i nā codons 12 a me 13 o K-ras gene i hoʻohana ʻia no ka ʻike qualitative o DNA i unuhi ʻia mai nā ʻāpana pathological i hoʻokomo ʻia i ke kanaka i loko o vitro.
1. ʻO ka hoʻokomoʻana i ka mana o ka mana o loko o ka'ōnaehana hiki ke nānā pono i ke kaʻina hana hoʻokolohua a hōʻoia i ka maikaʻi hoʻokolohua.
2. High sensitivity: hiki ke ʻike paʻa ka mutation rate o 1% i ke kua o 3ng/μL wild-type nucleic acid reaction solution.
3. Kiʻekiʻe kikoʻī: ʻaʻohe hopena keʻa me nā hopena ʻike o ka DNA genomic kanaka ʻano hihiu a me nā ʻano mutant ʻē aʻe.
ʻO ke kanaka ROS1 Fusion Gene Mutation Detection Kit (Fluorescence PCR)
Hoʻohana ʻia e ʻike pono i nā ʻano mutation 14 o ROS1 fusion gene i loko o nā mea maʻi maʻi maʻi ʻaʻa ʻole liʻiliʻi liʻiliʻi i loko o ka vitro.
1. ʻO ka hoʻokomoʻana i ka mana o ka mana o loko o ka'ōnaehana hiki ke nānā pono i ke kaʻina hana hoʻokolohua a hōʻoia i ka maikaʻi hoʻokolohua.
2. ʻIke kiʻekiʻe: 20 kope o ka fusion mutation.
3. Kiʻekiʻe kikoʻī: ʻaʻohe hopena keʻa me nā hopena ʻike o ka DNA genomic kanaka ʻano hihiu a me nā ʻano mutant ʻē aʻe.
ʻO ke kanaka EML4-ALK Fusion Gene Mutation Detection Kit (Fluorescence PCR)
Hoʻohana ʻia e ʻike pono i nā ʻano mutation 12 o EML4-ALK fusion gene i loko o nā mea maʻi maʻi maʻi ʻaʻai liʻiliʻi liʻiliʻi i loko o ka vitro.
1. ʻO ka hoʻokomoʻana i ka mana o ka mana o loko o ka'ōnaehana hiki ke nānā pono i ke kaʻina hana hoʻokolohua a hōʻoia i ka maikaʻi hoʻokolohua.
2. ʻIke kiʻekiʻe: 20 kope o ka fusion mutation.
3. Kiʻekiʻe kikoʻī: ʻaʻohe hopena keʻa me nā hopena ʻike o ka DNA genomic kanaka ʻano hihiu a me nā ʻano mutant ʻē aʻe.
ʻO ke kanaka BRAF Gene V600E Mutation Detection Kit (Fluorescence PCR)
Hoʻohana ʻia ia e ʻike pono i ka hoʻololi ʻana o ka BRAF gene V600E i nā laʻana o ka melanoma kanaka, colorectal cancer, thyroid cancer and lung cancer in vitro.
1. ʻO ka hoʻokomoʻana i ka mana o ka mana o loko o ka'ōnaehana hiki ke nānā pono i ke kaʻina hana hoʻokolohua a hōʻoia i ka maikaʻi hoʻokolohua.
2. High sensitivity: hiki ke ʻike paʻa ka mutation rate o 1% i ke kua o 3ng/μL wild-type nucleic acid reaction solution.
3. Kiʻekiʻe kikoʻī: ʻaʻohe hopena keʻa me nā hopena ʻike o ka DNA genomic kanaka ʻano hihiu a me nā ʻano mutant ʻē aʻe.
'ikamu helu | Inoa Huahana | Hōʻike |
HWTS-TM006 | ʻO ke kanaka EML4-ALK Fusion Gene Mutation Detection Kit (Fluorescence PCR) | 20 ho'āʻo/kit 50 ho'āʻo / pahu |
HWTS-TM007 | ʻO ke kanaka BRAF Gene V600E Mutation Detection Kit (Fluorescence PCR) | 24 hōʻike / pahu 48 hōʻike / pahu |
HWTS-TM009 | ʻO ke kanaka ROS1 Fusion Gene Mutation Detection Kit (Fluorescence PCR) | 20 ho'āʻo/kit 50 ho'āʻo / pahu |
HWTS-TM012 | Kāne EGFR Gene 29 Mutations Detection Kit (Fluorescence PCR) | 16 ho'āʻo/kit 32 ho'āʻo/kit |
HWTS-TM014 | KRAS 8 Mutations Detection Kit (Fluorescence PCR) | 24 hōʻike / pahu 48 hōʻike / pahu |
HWTS-TM016 | ʻO ke kanaka TEL-AML1 Fusion Gene Mutation Detection Kit (Fluorescence PCR) | 24 hōʻike / pahu |
HWTS-GE010 | ʻO ke kanaka BCR-ABL Fusion Gene Mutation Detection Kit (Fluorescence PCR ) | 24 hōʻike / pahu |
Ka manawa hoʻouna: Apr-17-2024